Antidiabetic Medication-Induced Acute Interstitial Nephritis: Case Report and Literature Search

References for Table 2

Gariani K, de Seigneux S, Moll S. Acute interstitial nephritis after treatment with liraglutide. Am J Kidney Dis 2014;63(2):347. https://doi.org/10.1053/j.ajkd.2013.10.057

Dubois-Laforgue D, Boutboul D, Lévy DJ, et al. Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists. Diabetes Res Clin Pract 2014; 103(3):e53–5. https://doi.org/10.1016/j.diabres. 2013.11.014

Bhatti R, Flynn MD, Illahi M, et al. Exenatide associated renal failure. Pract Diabetes Int 2010;27(6):232–4.

Nandakoban H, Furlong TJ, Flack JR. Acute tubulointerstitial nephritis following treatment with exenatide. Diabet Med 2013;30(1):123–5. https://doi.org/10.1111/j.1464-5491.2012.03738.x

Leehey DJ, Rahman MA, Borys E, et al. Acute kidney injury associated with semaglutide. Kidney Med 2021;3(2):282–5. https://doi.org/10.1016/j.xkme.2020.10.008

Taylor SR, Moody MT. Acute kidney injury occurring in a patient initiated on dulaglutide. J Pharm Technol 2018;34(5):231–2. https://doi.org/10.1177/8755122518782155

Ryan R, Choo S, Willows J, et al. Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin. Clin Kidney J 2020;14(3): 1020–2. https://doi.org/10.1093/ckj/sfaa033

Bnaya A, Itzkowitz E, Atrash J, et al. Acute intersitital nephritis related to empagliflozin. Nephrol Dialysis Transplant 2020;35(Suppl 3). https://doi.org/10.1093/ndt/gfaa142.P0580

Gribben WB, Decker G. Canagliflozin-induced acute interstitial nephritis. J Hosp Med 2021;11(Suppl 1).

Lin DY, Hoffman D, Pulivarti VV, Abendroth CS, Pulivarti B. Sitagliptin caused acute drug induced interstitial nephritis. Consultant 2014;54(6): 444–6.

Alsaad AA, Dhannoon SM, Pantin SA, et al. Rare allergic reaction of the kidney: sitagliptin-induced acute tubulointerstitial nephritis. BMJ Case Rep 2016;2016: bcr2016216297. https://doi.org/10.1136/bcr-2016-216297

Shima H, Okamoto T, Tashiro M, et al. Alogliptin-induced minimal change nephrotic syndrome and interstitial nephritis. Kidney Med 2019;1(2):75–8. https://doi.org/10.1016/j.xkme.2019.03.001

Oyama S, Hosohata K, Inada A, et al. Drug-induced tubulointerstitial nephritis in a retrospective study using spontaneous reporting system database. Ther Clin Risk Manag 2018;14:1599–604. https://doi.org/10.2147/TCRM.S168696

Akbar S, Goldblat M, Palekar S, et al. A rare case of interstitial nephritis with secondary membranous glomerulopathy due to glimepiride. Am J Kidney Dis 2010;55(4);836. https://doi.org/10.1053/j.ajkd.2010.02.027

Castledine C, Wright D, Kingdon E. Rosiglitazone as a cause of acute interstitial nephritis. Nephrol Dial Transplant 2006;21(7):1994–5. https://doi.org/10.1093/ndt/gfl045

Abdul Ghani R, Zainudin S, Kamaruddin NA, et al. Acute renal failure following the use of rosiglitazone in a chronic kidney disease patient. Singapore Med J 2009;50(1):e32–4.

References

MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002;51(Suppl 3):S434–42. https://doi.org/10.2337/diabetes.51.2007.s434

Yin WL, Bain SC, Min T. The effect of glucagon-like peptide-1 receptor agonists on renal outcomes in type 2 diabetes. Diabetes Ther 2020; 11(4):835–44. https://doi.org/10.1007/s13300-020-00798-x

Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375(4):311–22. https://doi.org/10.1056/NEJMoa1603827

Mann JFE, Ørsted DD, Brown-Frandsen K, et al; LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017;377(9):839–48. https://doi.org/10.1056/NEJMoa1616011

Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care 2016;39(2):222–30. https://doi.org/10.2337/dc14-2883

Gariani K, de Seigneux S, Moll S. Acute interstitial nephritis after treatment with liraglutide. Am J Kidney Dis 2014;63(2):347. https://doi.org/10.1053/j.ajkd.2013.10.057

Goicoechea M, Rivera F, López-Gómez JM; Spanish Registry of Glomerulonephritis. Increased prevalence of acute tubulointerstitial nephritis. Nephrol Dial Transplant 2013;28(1):112–5. https://doi.org/10.1093/ndt/gfs143

Moledina DG, Perazella MA. Treatment of drug-induced acute tubulointerstitial nephritis: the search for better evidence. Clin J Am Soc Nephrol 2018; 13(12):1785–7. https://doi.org/10.2215/CJN.12001018

Moledina DG, Perazella MA. Drug-induced acute interstitial nephritis. Clin J Am Soc Nephrol 2017;12(12):2046–9. https://doi.org/10.2215/CJN.07630717

Shah S, Carter-Monroe N, Atta MG. Granulomatous interstitial nephritis. Clin Kidney J 2015;8(5):516–23. https://doi.org/10.1093/ckj/sfv053

Perazella MA. Clinical approach to diagnosing acute and chronic tubulointerstitial disease. Adv Chronic Kidney Dis 2017;24(2):57–63. https://doi.org/10.1053/j.ackd.2016.08.003

Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol 2010;6(8):461–70. https://doi.org/10.1038/nrneph.2010.71

Vistisen D, Andersen GS, Hulman A, et al. Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function - even without albuminuria. Diabetes Care 2019; 42(10):1886–94. https://doi.org/10.2337/dc19-0349

Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab 2011;96(6):1695–702. https://doi.org/10.1210/jc.2010-2822

Ramachandran R, Kumar K, Nada R, et al. Drug-induced acute interstitial nephritis: a clinicopathological study and comparative trial of steroid regimens. Indian J Nephrol 2015;25(5):281–6. https://doi.org/10.4103/0971-4065.147766

Prendecki M, Tanna A, Salama AD, et al. Long-term outcome in biopsy-proven acute interstitial nephritis treated with steroids. Clin Kidney J 2017; 10(2):233–9. https://doi.org/10.1093/ckj/sfw116

Clarkson MR, Giblin L, O'Connell FP, et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant 2004;19(11):2778–83. https://doi.org/10.1093/ndt/gfh485

Valluri A, Hetherington L, Mcquarrie E, et al. Acute tubulointerstitial nephritis in Scotland. QJM 2015;108(7):527–32. https://doi.org/10.1093/qjmed/hcu236

Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am J Kidney Dis 2014;64(4):558–66. https://doi.org/10.1053/j.ajkd.2014.04.027

Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, et al. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes 2015;6(8):1073–81. https://doi.org/10.4239/wjd.v6.i8.1073

Surendra M, Raju S, Chandragiri S, et al. Steroid therapy in drug induced acute interstitial nephritis: retrospective analysis of 83 cases. Saudi J Kidney Dis Transpl 2019;30(1):157–165.

Dubois-Laforgue D, Boutboul D, et al. Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists. Diabetes Res Clin Pract 2014;103(3):e53–5. https://doi.org/10.1016/j.diabres.2013.11.014

Bhatti R, Flynn MD, Illahi M, et al. Exenatide associated renal failure. Pract Diabetes Int 2010;27(6):232–4.